Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NRX Pharmaceuticals (NRXP) Notes Payables (2024 - 2025)

NRX Pharmaceuticals (NRXP) has disclosed Notes Payables for 2 consecutive years, with $9.9 million as the latest value for Q3 2025.

  • Quarterly Notes Payables rose 224.89% to $9.9 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $9.9 million through Sep 2025, up 224.89% year-over-year, with the annual reading at $1.2 million for FY2024, N/A changed from the prior year.
  • Notes Payables for Q3 2025 was $9.9 million at NRX Pharmaceuticals, up from $9.9 million in the prior quarter.
  • The five-year high for Notes Payables was $9.9 million in Q3 2025, with the low at $1.2 million in Q4 2024.